Tvardi Therapeutics Expected to Report Q3 Loss of 35 Cents Per Share

Summary

Tvardi Therapeutics Inc is expected to report a loss of 35 cents per share for the quarter ending March 31, 2025, with a decline in revenue. Analysts have an average rating of ‘Buy,’ with a 12-month median target price of $39.00, compared to the last closing price of $25.61. The report is scheduled for release on May 12, 2025. Reuters

Impact Analysis

1. Business Overview Analysis:

• Business Model: Tvardi Therapeutics operates in the biopharmaceutical sector, focusing on developing new oral small molecule therapies targeting STAT3 for diseases caused by fibrosis. GlobeNewswire+ 2
• Market Position: Following the recent merger with Cara Therapeutics, the company is poised to strengthen its presence with approximately 940 million shares available for trade under the symbol ‘TVRD’. GlobeNewswire
• Recent Events Impact: The completion of the merger with Cara Therapeutics and the new stock symbol are significant moves that could enhance market visibility and investor interest. Benzinga

2. Financial Statement Analysis:

• Income Statement: The expected loss of $0.35 per share indicates financial pressure, possibly due to ongoing R&D and merger costs.
• Key Metrics:
• Profitability: Current outlook suggests a challenge in achieving profitability due to anticipated losses per share.
• Liquidity: Detailed metrics on liquidity aren’t provided, but analysts’ ‘Buy’ rating suggests confidence in future financial stability.
• Solvency: The merger might impact debt/equity metrics, but specifics are not disclosed.
• Efficiency: Given the industry, asset turnover could be low with high R&D investments impacting short-term efficiency.

3. Valuation Assessment:

• The analyst target price of $39.00 indicates potential upside compared to the current price of $25.61, reflecting optimism about future growth post-merger. Reuters

4. Opportunity Analysis:

• Strategic opportunities may arise from the merger, allowing for enhanced capabilities and potential new drug developments targeting fibrosis-related conditions.

Risks:

• The loss per share and decreased revenue pose challenges that could affect short-term investor sentiment and require careful management to maintain investor confidence. Reuters